Scott Talbot

Cooley advised Tendyne in the development of its patent portfolio and in defending IP diligence in its $250M acquisition by global healthcare company Abbott. Tendyne’s bioprosthetic mitral valve system can provide treatment for mitral valve disease without the need for open heart surgery.

"The Tendyne acquisition broadens Abbott's foundation as a leader in treatments for mitral valve disease, which is highly complex and requires multiple treatment options," said John M. Capek, PhD, executive vice president, Ventures, Abbott.

Cooley advised Harpoon Medical in the development of its patent portfolio and in defending IP diligence in its $100M acquisition by Edwards Lifesciences, a leader in medical innovations for structural heart disease. Harpoon’s device is a less invasive alternative for mitral valve repair, designed to shorten the duration of the procedure and recovery period.

"We believe the addition of Harpoon Medical's technology and talented team will enable even more opportunities to help patients with degenerative mitral regurgitation," said Bernard Zovighian, Edwards' corporate vice president, surgical heart valve therapy.

Cooley advised Tusker Medical in the development of its patent portfolio and in defending IP diligence in its acquisition by Smith & Nephew. Tusker Medical’s Tula System, an in-office ear tube delivery system to treat recurrent or persistent ear infections, is helpful in treating children and removing the risk of general anesthesia for patients. With the acquisition of Tusker Medical, Smith & Nephew is looking forward to broaden the launch of Tula to improve quality of life for children who suffer from ear infections.

Cooley advised PureWick in the development of its patent portfolio and in defending IP diligence in its $30M acquisition by CR Bard. The PureWick system is an innovating option to managing female urinary incontinence, and is used in over 2,000 hospitals and rehab facilities as well as at home.

Cooley advised Farapulse in the development of its patent portfolio and in defending IP diligence in its $295M acquisition by Boston Scientific. Farapulse’s Pulsed Field Ablation (“PFA”) system is a novel, non-thermal method for cardiac ablation that is fundamentally different from traditional modalities.

Boston Scientific rhythm management and global health policy senior vice-president and chief medical officer Kenneth Stein said, “The emerging field of PFA has the potential to alter the future of ablation therapy and has shown the promise of improvements in both safety of cardiac ablations for patients and efficiency and ease-of-use of these procedures for physicians. The FARAPULSE PFA System is intended to enable physicians to precisely ablate cardiac tissue while minimizing procedural complications, and real-world and clinical evidence from trials throughout Europe have demonstrated encouraging, positive results.”